We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+1.18%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$254M
AUM Growth
+$704K
Cap. Flow
+$22.4M
Cap. Flow %
8.85%
Top 10 Hldgs %
43.68%
Holding
90
New
20
Increased
18
Reduced
11
Closed
40

Top Buys

Rank Stock Value
1
PRAH
PRA Health Sciences, Inc.
PRAH
+$9.28M
2
TAK icon
Takeda Pharmaceutical
TAK
+$9.02M
3
SIEN
Sientra, Inc.
SIEN
+$8.62M
4
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$8.05M
5
HUM icon
Humana
HUM
+$7.05M

Top Sells

Rank Stock Value
1
ICLR icon
Icon
ICLR
+$13.8M
2
GILD icon
Gilead Sciences
GILD
+$10.1M
3
BMY icon
Bristol-Myers Squibb
BMY
+$9.55M
4
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
+$5.99M
5
EVH icon
Evolent Health
EVH
+$5.27M

Sector Composition

Rank Sector Weight
1 Healthcare 83.86%
2 Technology 6.14%
3 Miscellaneous 5.87%
4 Industrials 4.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
26
Bristol-Myers Squibb
BMY
$128B
$3.91M 1.54%
86,297
-204,984
-70% -$9.55M
LQDA icon
27
Liquidia Corp
LQDA
$6.12B
$3.75M 1.48%
468,981
+233,652
+99% +$2.19M
ACRS icon
28
Aclaris Therapeutics
ACRS
$795M
$3.57M 1.41%
1,629,327
+1,083,598
+199% +$5.91M
GWPH
29
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.14M 1.24%
+18,210
New +$3.15M
IART icon
30
Integra LifeSciences
IART
$1.17B
$2.39M 0.94%
+42,827
New +$2.21M
SGRY icon
31
Surgery Partners
SGRY
$1.75B
$2.34M 0.92%
287,720
+248,915
+641% +$2.48M
NTGN
32
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
$2.21M 0.87%
465,650
+40,359
+9% +$226K
RVLP
33
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$1.95M 0.77%
514,239
+234,678
+84% +$780K
DVA icon
34
DaVita
DVA
$11.7B
$1.83M 0.72%
+32,566
New +$1.69M
GRTS
35
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$1.6M 0.63%
143,752
+122,495
+576% +$1.4M
MRNS
36
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.5M 0.59%
90,547
-18,778
-17% -$326K
SIBN icon
37
SI-BONE Inc
SIBN
$809M
$1.33M 0.52%
+65,216
New +$1.12M
TNDM icon
38
Tandem Diabetes Care
TNDM
$1.2B
$1.26M 0.5%
+19,579
New +$1.26M
BIO icon
39
Bio-Rad Laboratories Class A
BIO
$10.2B
$1.17M 0.46%
+3,735
New +$1.12M
GNCA
40
DELISTED
Genocea Biosciences, Inc.
GNCA
$1.14M 0.45%
+289,714
New +$1.51M
MD icon
41
Pediatrix Medical
MD
$2.07B
$994K 0.39%
+39,401
New +$1.06M
ATNM icon
42
Actinium Pharmaceuticals
ATNM
$37.4M
$610K 0.24%
+82,712
New +$831K
SRPT icon
43
Sarepta Therapeutics
SRPT
$2.18B
$570K 0.22%
3,753
-10,611
-74% -$1.29M
ALGN icon
44
Align Technology
ALGN
$10.6B
$537K 0.21%
1,962
-4,595
-70% -$1.39M
CBIO
45
Crescent Biopharma
CBIO
$623M
$504K 0.2%
+423
New +$506K
TBIO
46
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$490K 0.19%
+38,772
New +$409K
ADVM
47
DELISTED
Adverum Biotechnologies
ADVM
$379K 0.15%
+3,187
New +$264K
A icon
48
Agilent Technologies
A
$44.1B
– –
-12,583
Closed -$1.01M
ABT icon
49
Abbott
ABT
$177B
– –
-23,966
Closed -$1.92M
ALDX icon
50
Aldeyra Therapeutics
ALDX
$83.3M
– –
-23,576
Closed -$213K
1
2
3 4

Similar funds

UVM
Upfront Ventures Management Santa Monica, California $12.3M AUM
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Endurant Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Endurant Capital Management held 90 positions worth $254M, up 0.28% from $253M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Endurant Capital Management deployed $22.4M of net new capital in Q2 2019, opening 20 new positions and adding to 18 existing holdings. Its largest new stake was PRA Health Sciences, Inc.: 97,200 shares worth $9.64M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 76% a quarter earlier, followed by Technology and Miscellaneous.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $9.55M trimmed.

  • Endurant Capital Management's largest Q2 2019 buy was PRA Health Sciences, Inc.: 97,200 shares worth $9.64M.
  • Endurant Capital Management added most to Takeda Pharmaceutical in Q2 2019, an estimated $9.02M increase.
  • Endurant Capital Management's biggest Q2 2019 reduction was Bristol-Myers Squibb, cutting an estimated $9.55M.
  • Endurant Capital Management fully exited Icon in Q2 2019, selling an estimated $13.8M.
  • Endurant Capital Management's ten largest holdings make up 44% of its $254M portfolio in Q2 2019.
  • Endurant Capital Management opened 20 new positions and closed 40 in Q2 2019.
  • Endurant Capital Management's portfolio value rose 0.28% quarter-over-quarter to $254M.

Based on Endurant Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.